Key business considerations when developing biosimilar products virtually.
Anjan Selz
Advertisement
Anjan Selz is CEO and co-founder of Finox Biotech
Articles by Anjan Selz
How does working in a virtual biotech environment affect biosimilar development? Anjan Selz outlines target and partner selection in this first of a two part article.
Virtual biotech CEO Anjan Selz focuses on product development, credibility and differentiation.
Advertisement
Latest Updated Articles
- The Drive for Best Practice in Biopharmaceutical Manufacturing
Published: March 1st 2012 | Updated:
Biosimilar development in a virtual biotech set-up - Part IPublished: December 5th 2011 | Updated:
- Biosimilar Development in a Virtual Biotech Environment - Part II
Published: December 5th 2011 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
